17/03/22
Quality-of-life data from the ENZAMET trial showed greater initial declines in some areas with enzalutamide compared with physician's choice of bicalutamide, nilutamide, or flutamide, in men with recently diagnosed, metastatic hormone-sensitive prostate cancer, but there were overall benefits out to 3 years due to delayed disease progression, researchers reported.
In this exclusive MedPage Today interview, Eric A. Klein, MD, emeritus chair of the Glickman Urological and Kidney Institute and professor of surgery in the Lerner College of Medicine of the Cleveland Clinic, discusses his takeaways from the study.
